PE20080406A1 - Pirazoles como activadores de glucoquinasa - Google Patents

Pirazoles como activadores de glucoquinasa

Info

Publication number
PE20080406A1
PE20080406A1 PE2007000954A PE2007000954A PE20080406A1 PE 20080406 A1 PE20080406 A1 PE 20080406A1 PE 2007000954 A PE2007000954 A PE 2007000954A PE 2007000954 A PE2007000954 A PE 2007000954A PE 20080406 A1 PE20080406 A1 PE 20080406A1
Authority
PE
Peru
Prior art keywords
pirazoles
azoniabiciclo
trifluorbenzyl
fluorphenyl
carbamoyloxy
Prior art date
Application number
PE2007000954A
Other languages
English (en)
Inventor
Steven Joseph Berthel
Robert Francis Kester
Douglas Eric Murphy
Thomas Jay Prins
Frank Ruebsam
Ramakanth Sarabu
Chin Viet Tran
Dionisios Vourloumis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20080406A1 publication Critical patent/PE20080406A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA Ic DONDE R1 ES F, Cl, Br, ENTRE OTROS; R2 ES 3,4,5-TRIFLUORFENILO; 3,4-DIFLUORFENILO, ENTRE OTROS; X ES UN ANION. SON COMPUESTOS PREFERIDOS: (3R)-3-[(3-FLUOROFENIL)-(3,4,5-TRIFLUORBENCIL)-CARBAMOILOXI]-1-(2-OXO-2-FENILETIL)-1-AZONIABICICLO[2.2.2]OCTANO, BROMURO; (3R)-3-[(3-FLUORFENIL) -(3,4,5-TRIFLUORBENCIL)-CARBAMOILOXI]-1-(2-OXO-2-(4-FLUORFENIL)ETIL)-1-AZONIABICICLO[2.2.2]OCTANO-BROMURO; ENTRE OTROS. SE REFIERE TAMBIEN UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON MODULADORES DEL RECEPTOR MUSCARINICO M3, UTILES EN EL TRATAMIETO Y PREVENCION DE ENFERMEDADES RESPIRATORIAS TALES COMO ASMA, BRONQUITIS CRONICA, ENFISEMA Y DEMAS RELACIONADAS
PE2007000954A 2006-07-24 2007-07-23 Pirazoles como activadores de glucoquinasa PE20080406A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83290706P 2006-07-24 2006-07-24
US93081907P 2007-05-18 2007-05-18

Publications (1)

Publication Number Publication Date
PE20080406A1 true PE20080406A1 (es) 2008-04-28

Family

ID=38657003

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000954A PE20080406A1 (es) 2006-07-24 2007-07-23 Pirazoles como activadores de glucoquinasa

Country Status (16)

Country Link
US (1) US7935699B2 (es)
EP (2) EP2261216A3 (es)
JP (1) JP2009544648A (es)
KR (1) KR20090025358A (es)
AR (1) AR062012A1 (es)
AU (1) AU2007278261A1 (es)
BR (1) BRPI0715531A2 (es)
CA (1) CA2657566A1 (es)
CL (1) CL2007002121A1 (es)
IL (1) IL196321A0 (es)
MX (1) MX2009000688A (es)
NO (1) NO20090064L (es)
PE (1) PE20080406A1 (es)
RU (1) RU2009105818A (es)
TW (1) TWI332948B (es)
WO (1) WO2008012227A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2116533B1 (en) 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
AU2009205070A1 (en) * 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
SI2275414T1 (sl) 2008-04-28 2015-10-30 Kyorin Pharmaceutical Co., Ltd., Ciklopentilakrilamidni derivat
UA104742C2 (uk) * 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
EP2540908B1 (en) * 2010-02-23 2017-04-26 Seiren Co., Ltd. Moisture-permeable water-proof fabric
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
US8470866B2 (en) 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
CA2883535A1 (en) * 2012-09-26 2014-04-03 Kowa Company, Ltd. Novel phenylacetamide compound and pharmaceutical containing same
HUE040489T2 (hu) 2014-06-03 2019-03-28 Idorsia Pharmaceuticals Ltd Pirazolvegyületek és alkalmazásuk t-típusú kalciumcsatorna-blokkolókként
AU2015317022B2 (en) 2014-09-15 2020-01-16 Idorsia Pharmaceuticals Ltd Triazole compounds as T-type calcium channel blockers
TWI808952B (zh) 2016-12-16 2023-07-21 瑞士商愛杜西亞製藥有限公司 包含t型鈣通道阻斷劑之醫藥組合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
CN108727309B (zh) * 2018-06-20 2023-04-07 天津全和诚科技有限责任公司 一种3-氧杂环丁烷羧酸的合成方法
CN108947940A (zh) * 2018-06-20 2018-12-07 天津全和诚科技有限责任公司 一种2-氧杂环丁烷衍生物的合成方法
CN109053496B (zh) * 2018-08-09 2020-10-20 吉尔生化（上海）有限公司 一种3-Boc-氨甲基环丁酮的合成方法
CN114940658A (zh) * 2022-05-12 2022-08-26 山东华阳药业有限公司 一种色瑞替尼的制备工艺及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1169312E (pt) 1999-03-29 2005-01-31 Hoffmann La Roche Activadores de glicocinase
CN1176915C (zh) 2000-05-03 2004-11-24 霍夫曼-拉罗奇有限公司 炔基苯基芳香杂环的菊糖激酶激活剂
WO2001085707A1 (en) 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
JP3839723B2 (ja) 2000-05-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルアセトアミドおよびグルコキナーゼ活性化剤としてのその使用
ES2256340T3 (es) 2000-12-06 2006-07-16 F. Hoffmann-La Roche Ag Activadores heteroaromaticos fusionados de la glucoquinasa.
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
MXPA04010605A (es) 2002-04-26 2004-12-13 Hoffmann La Roche Fenilacetamidas substituidas y su uso como activadores de flucoquinasa.
EP1549626A1 (en) 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
AR045414A1 (es) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
US7432287B2 (en) * 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
KR20070007104A (ko) 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
EP2048137A1 (en) 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP4700684B2 (ja) 2004-04-02 2011-06-15 ノバルティス アーゲー ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
JP2007530631A (ja) 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
US20080242869A1 (en) 2004-04-21 2008-10-02 Matthew Fyfe Tri(Cyclo) Substituted Amide Compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
BRPI0514147A (pt) * 2004-08-12 2008-05-27 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
CN101137631A (zh) 2004-12-03 2008-03-05 转化技术制药公司 杂芳族葡糖激酶激活剂
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
US20110053910A1 (en) 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
BRPI0622262A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
US7514439B2 (en) 2005-07-11 2009-04-07 Mitsubishi Tanabe Pharma Corporation Oxime derivative and preparations thereof
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
KR20080040046A (ko) 2005-08-31 2008-05-07 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
WO2007051846A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
SI2463283T1 (sl) 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza

Also Published As

Publication number Publication date
EP2261216A3 (en) 2011-12-14
WO2008012227A2 (en) 2008-01-31
AU2007278261A1 (en) 2008-01-31
CA2657566A1 (en) 2008-01-31
TW200812974A (en) 2008-03-16
US20080021032A1 (en) 2008-01-24
TWI332948B (en) 2010-11-11
EP2046755A2 (en) 2009-04-15
MX2009000688A (es) 2009-01-30
IL196321A0 (en) 2009-09-22
BRPI0715531A2 (pt) 2014-06-24
EP2261216A2 (en) 2010-12-15
WO2008012227A8 (en) 2008-09-12
WO2008012227A3 (en) 2008-05-15
JP2009544648A (ja) 2009-12-17
US7935699B2 (en) 2011-05-03
AR062012A1 (es) 2008-08-10
CL2007002121A1 (es) 2008-02-22
RU2009105818A (ru) 2010-08-27
KR20090025358A (ko) 2009-03-10
NO20090064L (no) 2009-02-04

Similar Documents

Publication Publication Date Title
PE20080406A1 (es) Pirazoles como activadores de glucoquinasa
PE20080407A1 (es) Derivados de quinuclidina como antagonistas de m3
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
TW200745067A (en) Novel compounds
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
GB2465132A (en) Novel compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
MX2010008469A (es) Pirazolopirimidinas, procedimiento para su preparacion y su uso como medicina.
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20121480A1 (es) Aminopirimidinas como inhibidores de syk
GEP20146072B (en) New compounds
EA201101618A1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
TNSN08367A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2571876A4 (en) SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
JP2015520158A5 (es)
EA026385B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
NO20070088L (no) 1-, (3R)-amino-4-(2-fluor-fenyl)-butyl !-pyrrolidin-(2R)-karboksylsyre-benzyl amin derivater og beslektede forbindelser som dipeptidyl-peptidase IV (DPP??IV) inhibitorer for behandling av type 2
TW200616995A (en) Novel compounds
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
IN2012DN00721A (es)
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.

Legal Events

Date Code Title Description
FC Refusal